These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36461793)

  • 1. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
    Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
    Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    He Y; Shen Q; Fu W; Wang H; Song G
    Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Method for Reporting Prostate Cancer Grade in MRI-targeted Biopsies.
    Deng FM; Isaila B; Jones D; Ren Q; Kyung P; Hoskoppal D; Huang H; Mirsadraei L; Xia Y; Melamed J
    Am J Surg Pathol; 2022 Jan; 46(1):44-50. PubMed ID: 34115670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Gaffney CD; Tin AL; Fainberg J; Fine S; Jibara G; Touijer K; Eastham J; Scardino P; Laudone V; Vickers AJ; Ehdaie B
    Cancer; 2023 Dec; 129(23):3790-3796. PubMed ID: 37584213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Gleason Grading Group Upgrading in Low-Risk Prostate Cancer Patients From Transperineal Biopsy After Radical Prostatectomy.
    Zhou L; Xu LL; Zheng LL; Chen C; Xu L; Zeng JL; Li SY
    Acad Radiol; 2024 Jul; 31(7):2838-2847. PubMed ID: 38233258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of MRI-Targeted in-Bore Prostate Biopsy According to the Gleason Score with Postprostatectomy Histopathologic Control--a Targeted Biopsy-Only Strategy with Limited Number of Cores.
    Garmer M; Busch M; Mateiescu S; Fahlbusch DE; Wagener B; Grönemeyer DH
    Acad Radiol; 2015 Nov; 22(11):1409-18. PubMed ID: 26343218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biopsy-Integrated 3D Magnetic Resonance Imaging Modeling of Prostate Cancer and Its Application for Gleason Grade and Tumor Laterality Assessment.
    Kim J; Lim B; Jeong IG; Ro JY; Go H; Cho YM; Park KJ
    Arch Pathol Lab Med; 2023 Feb; 147(2):159-166. PubMed ID: 35512234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging-visible Lesions in Prostate Cancer Lead to Overtreatment?
    Baboudjian M; Diamand R; Uleri A; Beauval JB; Touzani A; Roche JB; Lacetera V; Roumeguère T; Simone G; Benamran D; Fourcade A; Gondran-Tellier B; Fiard G; Peltier A; Ploussard G
    Eur Urol; 2024 Sep; 86(3):232-237. PubMed ID: 38494379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
    Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
    Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of prebiopsy magnetic resonance imaging on biopsy and radical prostatectomy grade concordance.
    Shoag JE; Cai PY; Gross MD; Gaffney C; Li D; Mao J; Nowels M; Scherr DS; Sedrakyan A; Hu JC
    Cancer; 2020 Jul; 126(13):2986-2990. PubMed ID: 32320063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer.
    Payrard-Starck C; Fourcade A; An Nguyen T; Tissot V; Doucet L; Marolleau J; Lucas C; Fournier G; Valeri A
    Prog Urol; 2023 Apr; 33(5):265-271. PubMed ID: 36740508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Visible Tumor (PI-RADS ≥ 3) on Upgrading and Adverse Pathology at Radical Prostatectomy in Low Risk Prostate Cancer Patients: A Biopsy Core Based Analysis.
    Özkan A; Köseoğlu E; Kılıç M; Baydar DE; Sağlıcan Y; Balbay MD; Canda AE; Kordan Y; Kiremit MC; Çil B; Tuğcu V; Bakır B; Esen T
    Clin Genitourin Cancer; 2022 Feb; 20(1):e61-e67. PubMed ID: 34750082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted Biopsy Grade.
    Scuderi S; Pellegrino F; Tin A; Beech BB; Gandaglia G; Stabile A; Eastham JA; Montorsi F; Briganti A; Vickers AJ
    Eur Urol Focus; 2024 May; 10(3):486-488. PubMed ID: 37739916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients.
    Baco E; Ukimura O; Rud E; Vlatkovic L; Svindland A; Aron M; Palmer S; Matsugasumi T; Marien A; Bernhard JC; Rewcastle JC; Eggesbø HB; Gill IS
    Eur Urol; 2015 Apr; 67(4):787-94. PubMed ID: 25240973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis.
    Weinstein IC; Wu X; Hill A; Brennan D; Omil-Lima D; Basourakos S; Brant A; Lewicki P; Al Hussein Al Awamlh B; Spratt D; Bittencourt LK; Scherr D; Zaorsky NG; Nagar H; Hu J; Barbieri C; Ponsky L; Vickers AJ; Shoag JE
    Eur Urol Oncol; 2023 Aug; 6(4):355-365. PubMed ID: 37236832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusion-targeted biopsies.
    Gordetsky JB; Schultz L; Porter KK; Nix JW; Thomas JV; Del Carmen Rodriguez Pena M; Rais-Bahrami S
    Hum Pathol; 2018 Jun; 76():68-75. PubMed ID: 29551676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
    BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
    Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
    Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
    Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
    Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined multiple clinical characteristics for prediction of discordance in grade and stage in prostate cancer patients undergoing systematic biopsy and radical prostatectomy.
    Liu H; Tang K; Xia D; Peng E; Wang L; Chen Z
    Pathol Res Pract; 2020 Nov; 216(11):153235. PubMed ID: 33035728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.